BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/21/2022 8:16:14 AM | Browse: 624 | Download: 1352
 |
Received |
|
2021-06-17 14:59 |
|
Peer-Review Started |
|
2021-06-17 15:05 |
|
First Decision by Editorial Office Director |
|
2021-08-18 02:27 |
|
Return for Revision |
|
2021-08-18 02:27 |
|
Revised |
|
2021-08-30 08:15 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2021-12-06 03:29 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2021-12-08 06:10 |
|
Articles in Press |
|
2021-12-08 06:10 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-01-18 04:31 |
|
Publish the Manuscript Online |
|
2022-01-21 08:16 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Review |
| Article Title |
Is there a role of lipid-lowering therapies in the management of fatty liver disease?
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Ismini Tzanaki, Aris P Agouridis and Michael S Kostapanos |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Michael S Kostapanos, MD, MRCP, PhD, Consultant Physician-Scientist, General Medicine, Addenbrooke's Hospital, Cambridge University Hospitals, Hill's Road, Cambridge CB20QQ, United Kingdom. mk828@medschl.cam.ac.uk |
| Key Words |
Non-alcoholic fatty liver; Non-alcoholic steatohepatitis; Statin; Ezetimibe; Fibrates; ω-3 fatty acids; Bile acid resins |
| Core Tip |
Statins may be beneficial against NAFLD/NASH in association with their cholesterol-lowering efficacy as well as their anti-inflammatory, antioxidant and anti-fibrotic actions. Elimination of hepatic steatosis, inflammation and fibrosis was noted with statin use in the clinical setting of NAFLD/NASH. Experimental evidence suggests that ezetimibe has similar benefits to statins against NAFLD/NASH. However, ezetimibe was beneficial only against hepatic steatosis, but not against inflammation or fibrosis in NAFLD patients. Despite their promising mechanistic potential against NAFLD/NASH through PPARα activation benefits of fibrates on liver outcomes have not been established in clinical studies. Ample heterogeneous evidence suggests benefits of ω-3 fatty acids against hepatic steatosis, but not inflammation or fibrosis. |
| Publish Date |
2022-01-21 08:16 |
| Citation |
Tzanaki I, Agouridis AP, Kostapanos MS. Is there a role of lipid-lowering therapies in the management of fatty liver disease? World J Hepatol 2022; 14(1): 119-139 |
| URL |
https://www.wjgnet.com/1948-5182/full/v14/i1/119.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v14.i1.119 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
